{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:31:49Z","timestamp":1785209509662,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod. Sci."],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1177\/1933719114549850","type":"journal-article","created":{"date-parts":[[2014,9,17]],"date-time":"2014-09-17T04:56:26Z","timestamp":1410929786000},"page":"476-483","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["The Clinical Pharmacology and Pharmacokinetics of Ulipristal Acetate for the Treatment of Uterine Fibroids"],"prefix":"10.1007","volume":"22","author":[{"given":"Oliver","family":"Pohl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Howard","family":"Zobrist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Gotteland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,30]]},"reference":[{"issue":"9252","key":"22040476_CR1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(00)03622-9","volume":"357","author":"EA Stewart","year":"2001","unstructured":"Stewart EA. Uterine fibroids. Lancet. 2001;357(9252):293\u2013298.","journal-title":"Lancet"},{"issue":"5","key":"22040476_CR2","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1056\/NEJMe1114043","volume":"366","author":"EA Stewart","year":"2012","unstructured":"Stewart EA. Uterine fibroids and evidence-based medicine\u2013not an oxymoron. N Engl J Med. 2012;366(5):471\u2013473.","journal-title":"N Engl J Med"},{"issue":"1","key":"22040476_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.contraception.2010.02.011","volume":"82","author":"LB Zapata","year":"2010","unstructured":"Zapata LB, Whiteman MK, Tepper NK, Jamieson DJ, Marchbanks PA, Curtis KM. Intrauterine device use among women with uterine fibroids: a systematic review. Contraception. 2010;82(1):41\u201355.","journal-title":"Contraception"},{"issue":"6","key":"22040476_CR4","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S0015-0282(16)60723-9","volume":"51","author":"J Donnez","year":"1989","unstructured":"Donnez J, Schrurs B, Gillerot S, Sandow J, Clerckx F. Treatment of uterine fibroids with implants of gonadotropin-releasing hormone agonist: assessment by hysterography. Fertil Steril. 1989;51(6):947\u2013950.","journal-title":"Fertil Steril"},{"key":"22040476_CR5","unstructured":"Lethaby A, Vollenhoven B. Fibroids (uterine myomatosis, leiomyomas). Clin Evid (Online). 2011;pii:0814."},{"key":"22040476_CR6","unstructured":"Donnez J, Vazquez F, Tomaszewski J, et al. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril. 2014;pii:S0015-0282(14)00146-0."},{"key":"22040476_CR7","unstructured":"European Medicines Agency. Esmya - ulipristal. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002041\/human_med_001542.jsp&mid=WC0b01ac058001d124. Published March 15, 2012. Updated May 25, 2014."},{"key":"22040476_CR8","first-page":"177","volume":"5","author":"O Pohl","year":"2013","unstructured":"Pohl O, Kendrick J, Gotteland JP. Metabolic disposition of [14C] ulipristal acetate in healthy premenopausal women. J Bioequiv Availab. 2013;(5):177\u2013184.","journal-title":"J Bioequiv Availab"},{"key":"22040476_CR9","unstructured":"European Medicines Agency. CHMP assessment report for Ellaone. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/001027\/WC500023673.pdf. Published November 13, 2009. Updated September 23, 2013."},{"key":"22040476_CR10","unstructured":"European Medicines Agency. Esmya - Summary of Product Characteristics. Web site. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002041\/WC500124085.pdf. Published March 15, 2012. Updated May 25, 2014."},{"key":"22040476_CR11","unstructured":"Watson Laboratories Inc. Watson Laboratories study UL1102: An Open-Label, Crossover Study to Investigate the Effects of Multiple Doses of Ketoconazole on the Pharmacokinetics of a Single Dose of Ulipristal Acetate in Healthy Female Subjects. Study Report 2011."},{"issue":"6","key":"22040476_CR12","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/jcpt.12098","volume":"38","author":"O Pohl","year":"2013","unstructured":"Pohl O, Osterloh I, Gotteland JP. Effects of erythromycin at steady-state concentrations on the pharmacokinetics of ulipristal acetate. J Clin Pharm Ther. 2013;38(6):512\u2013517.","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"22040476_CR13","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/jcpt.12065","volume":"38","author":"O Pohl","year":"2013","unstructured":"Pohl O, Osterloh I, Gotteland JP. Ulipristal acetate - safety and pharmacokinetics following multiple doses of 10\u201350 mg per day. J Clin Pharm Ther. 2013;38(4):314\u2013320.","journal-title":"J Clin Pharm Ther"},{"key":"22040476_CR14","unstructured":"PregLem SA. PregLem study PGL12-011: Quantitative Predicition of Systemic Exposure to PGL4001 (Ulipristal Acetate) and the Effects of Concomitant CYP3A4 Inhibitors\/Inducers Using Prior in Vitro and in Vivo Data. Study Report 2012."},{"key":"22040476_CR15","unstructured":"PregLem S.A. PregLem study PGL12-010: Assessment of Potential Substrate and Inhibitor of PGL4001 of Efflux (BCRP and BSEP) and Uptake (OCT1, OCT2, OAT1, OAT3, OATP1B1 and OATP1B3) Transporter. Study Report 2012."},{"key":"22040476_CR16","unstructured":"PregLem S.A. PregLem study PGL09-007: P-gp Interaction Studies of Ulipristal Acetate and PGL4002 in Caco-2 Cell Monolayer System. Study Report 2009."},{"key":"22040476_CR17","unstructured":"Watson Laboratories Inc. Watson Laboratories study UL1105: An Open-Label, Crossover Study to Assess the Effects of 10 mg Ulipristal Acetate on the Pharmacokinetics of Fexofenadine (Allegra) in Healthy Female Subjects. Study Report 2012."},{"issue":"2","key":"22040476_CR18","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/01.AOG.0000136079.62513.39","volume":"104","author":"EE Wallach","year":"2004","unstructured":"Wallach EE, Vlahos NF. Uterine myomas: an overview of development, clinical features, and management. Obstet Gynecol. 2004;104(2):393\u2013406.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"22040476_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2165\/00003088-198917020-00002","volume":"17","author":"E Harju","year":"1989","unstructured":"Harju E. Clinical pharmacokinetics of iron preparations. Clin Pharmacokinet. 1989;17(2):69\u201389.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"22040476_CR20","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.1365-2125.1991.tb05525.x","volume":"31","author":"NR Campbell","year":"1991","unstructured":"Campbell NR, Hasinoff BB. Iron supplements: a common cause of drug interactions. Br J Clin Pharmacol. 1991;31(3): 251\u2013255.","journal-title":"Br J Clin Pharmacol"},{"key":"22040476_CR21","unstructured":"Watson Laboratories Inc. Watson Laboratories study UL1103: An Open-Label, Crossover Study to Investigate the Effects of Oral Iron Administration on the Pharmacokinetics of a Single 10 mg Dose of Ulipristal Acetate in Healthy Female Subjects. Study Report 2012."},{"key":"22040476_CR22","unstructured":"Watson Laboratories Inc. Watson Laboratories study UL1101: An Open-Label, Crossover, Comparative Bioavailability Study of 10 mg Ulipristal Acetate After a High-Fat Meal or Under Fasting Conditions. Study Report 2011."},{"issue":"1","key":"22040476_CR23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5414\/CP201789","volume":"51","author":"O Pohl","year":"2013","unstructured":"Pohl O, Osterloh I, Lecomte V, Gotteland JP. Changes in gastric pH and in pharmacokinetics of ulipristal acetate - a drug-drug interaction study using the proton pump inhibitor esomeprazole. Int J Clin Pharmacol Ther. 2013;51(1):26\u201333.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"5","key":"22040476_CR24","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1056\/NEJMoa1103182","volume":"366","author":"J Donnez","year":"2012","unstructured":"Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366(5):409\u2013420.","journal-title":"N Engl J Med"},{"issue":"5","key":"22040476_CR25","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1056\/NEJMoa1103180","volume":"366","author":"J Donnez","year":"2012","unstructured":"Donnez J, Tomaszewski J, Vazquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012;366(5):421\u2013432.","journal-title":"N Engl J Med"},{"key":"22040476_CR26","unstructured":"Watson Laboratories Inc. Watson Laboratories study UL1106: An Open-Label, Prospective Study to Evaluate the Pharmacokinetics and Safety of a Single Oral 10 mg Dose of Ulipristal Acetate in Female Subjects with Moderately Impaired Hepatic Function Compared to Healthy Matched Subjects with Normal Hepatic Function. Study Report 2012."},{"issue":"10","key":"22040476_CR27","first-page":"1119","volume":"25","author":"GR Jang","year":"1997","unstructured":"Jang GR, Benet LZ. Cytochrome P4503A4-mediated N-demethylation of the antiprogestins lilopristone and onapristone. Drug Metab Dispos. 1997;25(10):1119\u20131122.","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"22040476_CR28","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1124\/dmd.30.9.985","volume":"30","author":"KK Khan","year":"2002","unstructured":"Khan KK, He YQ, Correia MA, Halpert JR. Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: selective inactivation of P450 3A4. Drug Metab Dispos. 2002;30(9):985\u2013990.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"22040476_CR29","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0378-4347(00)83757-3","volume":"532","author":"C Zurth","year":"1990","unstructured":"Zurth C, Kagels F. Determination of onapristone and its N-desmethyl metabolite in human plasma or serum by high-performance liquid chromatography. J Chromatogr. 1990;532(1):115\u2013123.","journal-title":"J Chromatogr"},{"issue":"3","key":"22040476_CR30","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jsbmb.2003.12.004","volume":"88","author":"BJ Attardi","year":"2004","unstructured":"Attardi BJ, Burgenson J, Hild SA, Reel JR. In vitro antiprogestational\/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J Steroid Biochem Mol Biol. 2004;88(3):277\u2013288.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"22040476_CR31","unstructured":"Watson Laboratories Inc. FIBRISTAL(TM) PRODUCT MONOGRAPH. http:\/\/www.fibristal.ca\/docs\/Fibristal_Product_Monograph_E.pdf. published on June 2013."},{"issue":"7","key":"22040476_CR32","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1517\/17425255.2012.695775","volume":"8","author":"GB Melis","year":"2012","unstructured":"Melis GB, Piras B, Marotto MF, et al. Pharmacokinetic evaluation of ulipristal acetate for uterine leiomyoma treatment. Expert Opin Drug Metab Toxicol. 2012;8(7):901\u2013908.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"10-13","key":"22040476_CR33","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S0039-128X(03)00118-1","volume":"68","author":"DL Blithe","year":"2003","unstructured":"Blithe DL, Nieman LK, Blye RP, Stratton P, Passaro M. Development of the selective progesterone receptor modulator CDB-2914 for clinical indications. Steroids. 2003;68(10\u201313):1013\u20131017.","journal-title":"Steroids"},{"issue":"9","key":"22040476_CR34","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1093\/humrep\/deg342","volume":"18","author":"MD Passaro","year":"2003","unstructured":"Passaro MD, Piquion J, Mullen N, et al. Luteal phase doseresponse relationships of the antiprogestin CDB-2914 in normally cycling women. Hum Reprod. 2003;18(9):1820\u20131827.","journal-title":"Hum Reprod"},{"issue":"9","key":"22040476_CR35","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1210\/jc.2006-2816","volume":"92","author":"N Chabbert-Buffet","year":"2007","unstructured":"Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2007;92(9):3582\u20133589.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Reproductive Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1177\/1933719114549850.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1933719114549850","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1177\/1933719114549850\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1933719114549850","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1177\/1933719114549850.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T01:33:30Z","timestamp":1656812010000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1177\/1933719114549850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["22040476"],"URL":"https:\/\/doi.org\/10.1177\/1933719114549850","relation":{},"ISSN":["1933-7191","1933-7205"],"issn-type":[{"value":"1933-7191","type":"print"},{"value":"1933-7205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"30 December 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}